Housrab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed to manage gastrointestinal disorders characterized by acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with gastroparesis and functional dyspepsia. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related disorders including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of Domperidone and Rabeprazole in Housrab-DSR Capsule offers comprehensive management by reducing gastric acidity and enhancing gastrointestinal motility, thus improving symptom control and promoting mucosal healing. This combination is typically prescribed for patients exhibiting symptoms of acid reflux accompanied by delayed gastric emptying. Housrab-DSR should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with cardiac conditions, electrolyte imbalances, or known hypersensitivity to either component. Regular monitoring is recommended to ensure efficacy and safety during treatment.